The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Alternative boosts === DNA-primed immune responses can be boosted by the administration of recombinant protein or recombinant poxviruses. "Prime-boost" strategies with recombinant protein have successfully increased both neutralising antibody titre, and antibody avidity and persistence, for weak immunogens, such as HIV-1 envelope protein. Recombinant virus boosts have been shown to be very efficient at boosting DNA-primed CTL responses. Priming with DNA focuses the immune response on the required immunogen, while boosting with the recombinant virus provides a larger amount of expressed antigen, leading to a large increase in specific CTL responses. Prime-boost strategies have been successful in inducing protection against malarial challenge in a number of studies. Primed mice with plasmid DNA encoding Plasmodium yoelii circumsporozoite surface protein (PyCSP), then boosted with a recombinant vaccinia virus expressing the same protein had significantly higher levels of antibody, CTL activity and IFN-γ, and hence higher levels of protection, than mice immunized and boosted with plasmid DNA alone. This can be further enhanced by priming with a mixture of plasmids encoding PyCSP and murine GM-CSF, before boosting with recombinant vaccinia virus. An effective prime-boost strategy for the simian malarial model P. knowlesi has also been demonstrated.
Delirium has been noted from discontinuation from clorazepate. A benzodiazepine dependence occurs in approximately one third of patients who take benzodiazepines for longer than 4 weeks, which is characterised by a withdrawal syndrome upon dose reduction. When used for seizure control, tolerance may manifest itself with an increased rate of seizures as well an increased risk of withdrawal seizures. In humans, tolerance to the anticonvulsant effects of clorazepate occurs frequently with regular use. Due to the development of tolerance, benzodiazepines are, in general, not considered appropriate for the long-term management of epilepsy; increasing the dose may result only in the developing of tolerance to the higher dose combined with worsened adverse effects. Cross-tolerance occurs between benzodiazepines, meaning that, if individuals are tolerant to one benzodiazepine, they will display a tolerance to equivalent doses of other benzodiazepines. Withdrawal symptoms from benzodiazepines include a worsening of pre-existing symptoms as well as the appearance of new symptoms that were not pre-existing. The withdrawal symptoms may range from mild anxiety and insomnia to severe withdrawal symptoms such as seizures and psychosis. Withdrawal symptoms can be difficult in some cases to differentiate between pre-existing symptoms and withdrawal symptoms. Use of high doses, long-term use and abrupt or over-rapid withdrawal increase the severity of withdrawal syndrome. However, tolerance to the active metabolite of clorazepate may occur more slowly than with other benzodiazepines.
The NCI continued to commission work to collect more Taxus bark and to isolate increasing quantities of taxol. By 1969, 28 kg (62 lb) of crude extract had been isolated from almost 1,200 kg (2,600 lb) of bark, although this ultimately yielded only 10 g (0.35 oz) of pure material, but for several years, no use was made of the compound by the NCI. In 1975, it was shown to be active in another in vitro system; two years later, a new department head reviewed the data and finally recommended taxol be moved on to the next stage in the discovery process. This required increasing quantities of purified taxol, up to 600 g (21 oz), and in 1977 a further request for 7,000 lb (3,200 kg) of bark was made. In 1978, two NCI researchers published a report showing that taxol was mildly effective in leukaemic mice. In November 1978, taxol was shown to be effective in xenograft studies. Meanwhile, taxol began to be well known in the cell biology, as well as the cancer communities, with a publication in early 1979 by Susan B. Horwitz, a molecular pharmacologist at Albert Einstein College of Medicine, showing that taxol had a previously unknown mechanism of action involving the stabilization of microtubules. Together with formulation problems, this increased interest from researchers meant that, by 1980, the NCI envisaged needing to collect 20,000 lb (9,100 kg) of bark. Animal toxicology studies were completed by June 1982, and in November, the NCI applied for the IND necessary to begin clinical trials in humans.
Generally, fatty acids (FAs) can be defined as organic compounds containing a carboxyl group (–COOH) at one end of an aliphatic hydrocarbon chain (also called the "front" end of the molecule), and a methyl group (–CH3) at the opposite end (also called the "methyl" end of the molecule). Fatty acid chains commonly contain anywhere from 4 to 24 carbon atoms, but they are known to reach up to 44 carbon atoms in length. Fatty acid chains typically contain an even number of carbon atoms (i.e., 10, 12, 16) and a linear structure about the acyl chain, though both odd-numbered and branched fatty acids also exist. Fatty acids can be categorized according to the degree of saturation (number of double bonds) present about the aliphatic hydrocarbon chain. Saturated fatty acids (SFAs) have no double bonds. Monounsaturated fatty acids (MUFAs) have one double bond, while polyunsaturated fatty acids (PUFAs) have two or more double bonds present about the acyl chain. Two discrete nomenclature systems are used for describing fatty acids: omega (ω–x) nomenclature and delta (Δ) nomenclature, in addition to simple common names. Within the fields of medicine and nutrition, both common names and omega nomenclature are frequently used to discuss fatty acids. In biochemistry and lipids research, fatty acid common names, omega nomenclature, and delta nomenclature are all widely used, but delta nomenclature is more typically seen in discussions on specific fatty acids. Additionally, common fatty acid names are often denoted alongside a shorthand notation (i.e., palmitic acid (C16:0)).
=== Marketing === Il-86 provision to Aeroflot did not constitute a sale: it was part of the centralised Soviet supply and allocation system coordinated by offices called Gosplan and Gossnab which controlled the entirety of planning and distribution in the USSR (except the black market). Built aircraft were allocated to Aeroflot regions and Soviet Air Force units as follows (in order of first acceptance): the Vnukovo Aviation Enterprise, 21 aircraft; the TsUMVS Administration of International Air Communications centred on Sheremetyevo Airport, 22; the Tashkent Air Enterprise, 9; the Sheremetyevo Air Enterprise, 10; the Pulkovo Air Enterprise, 8; the Alma-Ata Air Enterprise, 8; the Chkalovsky Soviet Air Force Base 8 ADON (or 8th Special Purposes Aviation Division), 4; the Kol'tsovo Air Enterprise, 6; the Tolmachevo Air Enterprise, 6; the Erevan Air Enterprise, 2; the Yemelyanovo Air Enterprise, 3. Selling the Il-86 commercially (which under the Soviet system meant solely exports) was the job of the Soviet foreign trade organisation V/O Aviaeksport. The division of responsibilities between the influential TsAGI research establishment, design bureaux (acting like naval architects) which designed aeroplanes, factories (independent of the bureaux) which constructed them, independent service facilities which repaired them and an independent organisation which marketed them alongside designs by all other bureaux, has been seen as diluting responsibility for the fate of a product.
Sources: en.wikipedia.org
== Examples and application of DNA ligases == Different types of ligases found in the studied organisms. For instance, Nicotinamide adenine dinucleotide (NAD+)-dependent ligase was found and isolated from bacterial organism, known as E. coli in second third of 20th century. Since then, this model has been widely used to study that DNA ligase family. Moreover, it is found in all bacteria. Examples of genes present in E. coli are LigA, which has essential functions affecting bacterial growth, and LigB. In mammals, including human 3 genes, namely Lig1, Lig3, Lig4 were identified. All eukaryotes contain multiple types of DNA ligases encoded by Lig genes. The smallest known eukaryotic ligase is Chlorella virus DNA ligase (ChVLig). It contains only 298 amino acids. When ChVLig is the only source of ligase in the cell, it can continue to support mitotic development, and nonhomologous end joining in budding yeasts. DNA Ligase I (Lig1) is accountable for Okazaki Fragments ligation. It is consist of 919 amino acids. In a complex process of DNA replication, DNA Ligase I recruited to replications machinery by protein interactions. Lig1 plays role in cell division in plants and yeasts. Knockout of the Lig1 gene is lethal in yeasts and some plants sprouts. Nevertheless, studies of mouse embryogenesis have shown that until the middle of the growth process embryo developing without DNA ligase I. Enzymatic ligation has been used in various studies related to DNA nanostructures and lead to increase of efficiency and stability.
In solid-state NMR spectroscopy, magic angle spinning is required to average out this orientation dependence in order to obtain frequency values at the average or isotropic chemical shifts. This is unnecessary in conventional NMR investigations of molecules in solution, since rapid "molecular tumbling" averages out the chemical shift anisotropy (CSA). In this case, the "average" chemical shift (ACS) or isotropic chemical shift is often simply referred to as the chemical shift.
== Structure and reactivity == Of the halobenzoquinones, DCBQ is the most commonly detected in drinking waters, up to 275 ng/L, and in chlorinated swimming pools, up to 299 ng/L. DCBQ can undergo hydrolysis, and its main hydrolysis product is DCBQ-OH. The transformation of DCBQ is much quicker in cell tissues than in water. The half-life of DCBQ is ~7h in water compared to ~1h in cell cultures, and is thus more reactive in cell tissues. In the human body, DCBQs can produce reactive oxidative species (ROS) at certain doses, causing mitochondrial dysfunction by reducing the mitochondrial membrane potential, and could promote the mitochondrial apoptosis pathway. DCBQ causes oxidative stress. DCBQ induced a concentration-dependent decrease in cell viability. It has also been found that DCBQ might cause nuclear DNA damage.
A feline litter usually consists of two to five kittens, but litters with one to more than ten are known. Kittens are typically born after a gestation lasting between 64 and 67 days, with an average length of 66 days. When they are born, kittens emerge in a sac called the amnion, which is bitten off and eaten by the mother cat. For the first several weeks, kittens cannot urinate or defecate without being stimulated by their mother. They also cannot regulate their body temperature for the first three weeks, so kittens born in temperatures less than 27 °C (81 °F) can die from hypothermia if their mother does not keep them warm. The mother's milk is very important for the kittens' nutrition and proper growth. This milk transfers antibodies to the kittens, which helps protect them against infectious diseases. As mentioned above, they cannot urinate, so they have a very high requirement for fluids. Kittens open their eyes about seven to ten days after birth. At first, the retina is poorly developed and vision is poor. Kittens cannot see as well as adult cats until about ten weeks after birth. Kittens develop very quickly from about two weeks of age until their seventh week. Their coordination and strength improve, and they play-fight with their littermates and begin to explore the world outside the nest or den. They learn to wash themselves and others as well as play hunting and stalking games, showing their inborn ability as predators; the kittens' mother or other adult cats help develop these innate skills by bringing live prey to the nest.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.